1) Novartis Oncology is conducting a study to determine the safety and efficacy of an investigational drug that is being tested in patients with imatinib-resistant or intolerant chronic myeloid leukemia in blast crisis, accelerated phase or chronic phase.. This study is being conducted in:
- Chicago, IL http://www.centerwatch.com/patient/studies/stu89510.html
- Chicago, IL http://www.centerwatch.com/patient/studies/stu89511.html
- Winston-Salem, NC http://www.centerwatch.com/patient/studies/stu89512.html
- Seattle, WA http://www.centerwatch.com/patient/studies/stu89513.html
--~--~---------~--~----~------------~-------~--~----~
[CMLHope]
A support group of http://cmlhope.com
-------------------------------------------------
You received this message because you are subscribed to the Google Groups "CMLHope" group.
To post to this group, send email to [email protected]
To unsubscribe from this group, send email to [EMAIL PROTECTED]
For more options, visit this group at http://groups.google.com/group/CMLHope
-~----------~----~----~----~------~----~------~--~---
